



# FOURTH-QUARTER AND FULL-YEAR 2022 RESULTS

## TOTAL COMPANY

### WORLDWIDE SALES





<b>FULL YEAR</b>	GROWTH ON AN ORGANIC BASIS*	<b>FOURTH QUARTER</b>
<b>\$43.7B</b>	<b>+6.4%<sup>1</sup></b>	<b>\$10.1B</b>

### ADJUSTED DILUTED EPS

<b>FULL YEAR</b>	<b>FOURTH QUARTER</b>
<b>\$5.34<sup>2</sup></b>	<b>\$1.03<sup>3</sup></b>

**EXCEEDED FULL-YEAR GUIDANCE ISSUED IN JANUARY 2022**  
**AT LEAST \$4.70<sup>4</sup> ADJUSTED DILUTED EPS**

## FULL-YEAR 2022: BUSINESS UNIT SALES

 <b>\$14.7B</b> MEDICAL DEVICES	 <b>\$16.6B</b> DIAGNOSTICS
 <b>\$7.5B</b> NUTRITION	 <b>\$4.9B</b> ESTABLISHED PHARMACEUTICALS


## FULL-YEAR 2023 GUIDANCE

**\$4.30 to \$4.50<sup>5</sup> ADJUSTED DILUTED EPS**

## BUSINESS HIGHLIGHTS

### NAVITOR™ TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) SYSTEM

- ▶ FDA approval adds to Abbott's comprehensive transcatheter structural heart portfolio
- ▶ Offers minimally invasive alternative to surgery for people with aortic stenosis, a common and life-threatening heart valve disease



**FREESTYLE LIBRE®\*\***  
 NAMED "BEST MEDICAL TECHNOLOGY" IN THE LAST 50 YEARS  
 BY THE GALIEN FOUNDATION



### ETERNA™ SPINAL CORD STIMULATION SYSTEM

- ▶ FDA approval of the world's smallest implantable, rechargeable spinal cord stimulation system for chronic pain<sup>6</sup>
- ▶ Patients can view real-time battery life and charging status updates via the mobile app for iPhone®



\*Organic sales growth excludes impact of foreign exchange. For full financial data and reconciliation of non-GAAP measures, please see our press release dated Jan. 25, 2023, available at [www.abbottinvestor.com](http://www.abbottinvestor.com).  
 \*\*Find important safety information about the FreeStyle Libre portfolio: [www.freestylelibre.us/safety-information](http://www.freestylelibre.us/safety-information).  
 ^ Smallest size determined by volume in cubic centimeters.

1. On a GAAP basis, full-year 2022 Abbott sales increased 1.3%. 2. Full-year 2022 GAAP diluted EPS was \$3.91. 3. Fourth-quarter GAAP diluted EPS was \$0.59. 4. Abbott projected full-year 2022 diluted EPS on a GAAP basis of \$3.75 to \$3.81. 5. Abbott projects full-year 2023 diluted earnings per share from continuing operations under GAAP of \$3.05 to \$3.25. Abbott forecasts specified items for the full-year 2023 of \$1.25 per share primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be \$4.30 to \$4.50 for the full-year 2023. 6. Abbott. Eterna SCS IPG Size Comparison Memo (MAT-2210151), 2022.

#### FORWARD-LOOKING STATEMENTS

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2021, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.